Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

211.86 -0.03 (-0.01%)
Streaming Delayed Price Updated: 10:20 AM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,459
Open 212.00
Bid (Size) 211.54 (4)
Ask (Size) 212.33 (4)
Prev. Close 211.89
Today's Range 211.00 - 216.31
52wk Range 189.44 - 278.95
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)
From Biogen Inc.
Via GlobeNewswire
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire

Performance

YTD
-20.86%
-20.86%
1 Month
-8.59%
-8.59%
3 Month
-1.38%
-1.38%
6 Month
-14.25%
-14.25%
1 Year
-21.59%
-21.59%

More News

Read More
The Analyst Verdict: Biogen In The Eyes Of 12 Experts
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Via The Motley Fool
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Via Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Via Investor's Business Daily
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
From Biogen Inc.
Via GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
Via Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
Via Investor's Business Daily
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
From Sage Therapeutics, Inc.
Via Business Wire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Via Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Via Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
From The Law Offices of Frank R. Cruz
Via Business Wire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
From Faruqi & Faruqi LLP
Via GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Via Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
BIOGEN INC. (NASDAQ: BIIB) SHAREHOLDER ALERT: Only 7 Days Remain For Investors To Move For Lead Plaintiff in Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.